

भारतीय भेषज संहिता आयोग

स्वास्थ्य एवं परिवार कल्याण मंत्रालय, भारत सरकार

सेक्टर - २३, राज नगर,

गाजियाबाद - २०१ ००२, उत्तर प्रदेश, भारत



INDIAN PHARMACOPOEIA COMMISSION

Ministry of Health & Family Welfare, Government of India

Sector - 23, Raj Nagar

Ghaziabad- 201 002 (U.P.), INDIA

File No. P.17019/03/2025-DSA

Dated: March 12, 2025

Monthly Drug Safety Alerts

The analysis of Adverse Drug Reactions (ADRs) from the PvPI database revealed the following;

S. No.	Suspected Drugs	Indication(s)	Adverse Drug Reactions
1	Metronidazole	For the treatment of amoebiasis, urogenital trichomoniasis & giardiasis.	Acute Generalised Exanthematous Pustulosis (AGEP)
2	Luliconazole	For the treatment of cutaneous mycosis viz. Tinea pedis, Tinea corporis and Tinea cruris.	Chloasma/Melasma
3	Dalteparin	For the extended treatment of symptomatic Venous Thromboembolism (VTE) proximal Deep Vein Thrombosis (DVT) and/or Pulmonary Embolism (PE) to reduce the recurrence of VTE in patients with cancer.	Muscle spasms
4	Gliclazide	Indicated for the treatment of all types of maturity onset diabetes, diabetes without or with obesity in adults.	Erythema multiforme
5	Tramadol	For the treatment of severe acute and chronic pain, diagnostic measures and surgical pain.	Fixed Drug Eruption

Healthcare Professionals, Patients/Consumers are advised to closely monitor the possibility of the above ADRs associated with the use of above suspected drugs. If, such reactions are encountered, please report to the NCC-PvPI, IPC by filling of Suspected Adverse Drug Reactions Reporting Form/Medicines Side Effect Reporting Form for Consumer (<http://www.ipc.gov.in>), through **PvPI Helpline No. 1800-180-3024**.